These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 26995301)

  • 21. Captopril and combination therapy of captopril and pentoxifylline in reducing proteinuria in diabetic nephropathy.
    Roozbeh J; Banihashemi MA; Ghezlou M; Afshariani R; Salari S; Moini M; Sagheb MM
    Ren Fail; 2010 Jan; 32(2):172-8. PubMed ID: 20199178
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pentoxifylline in diabetic kidney disease (VA PTXRx): protocol for a pragmatic randomised controlled trial.
    Leehey DJ; Carlson K; Reda DJ; Craig I; Clise C; Conner TA; Agarwal R; Kaufman JS; Anderson RJ; Lammie D; Huminik J; Polzin L; McBurney C; Huang GD; Emanuele NV
    BMJ Open; 2021 Aug; 11(8):e053019. PubMed ID: 34400461
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pentoxifylline and Methylprednisolone Additively Alleviate Kidney Failure and Prolong Survival of Rats after Renal Warm Ischemia-Reperfusion.
    Wystrychowski G; Wystrychowski W; Grzeszczak W; Więcek A; Król R; Wystrychowski A
    Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29324683
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Use of Curcumin for the Treatment of Renal Disorders: A Systematic Review of Randomized Controlled Trials.
    Bagherniya M; Soleimani D; Rouhani MH; Askari G; Sathyapalan T; Sahebkar A
    Adv Exp Med Biol; 2021; 1291():327-343. PubMed ID: 34331699
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of Pentoxifylline on Soluble Klotho Concentrations and Renal Tubular Cell Expression in Diabetic Kidney Disease.
    Navarro-González JF; Sánchez-Niño MD; Donate-Correa J; Martín-Núñez E; Ferri C; Pérez-Delgado N; Górriz JL; Martínez-Castelao A; Ortiz A; Mora-Fernández C
    Diabetes Care; 2018 Aug; 41(8):1817-1820. PubMed ID: 29866645
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A review of the potential benefits of pentoxifylline in diabetic and non-diabetic proteinuria.
    Badri S; Dashti-Khavidaki S; Lessan-Pezeshki M; Abdollahi M
    J Pharm Pharm Sci; 2011; 14(1):128-37. PubMed ID: 21501559
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The kidney and cardiovascular outcome trials.
    Bloomgarden Z
    J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of pentoxifylline on inflammatory parameters in chronic kidney disease patients: a randomized trial.
    Goicoechea M; García de Vinuesa S; Quiroga B; Verdalles U; Barraca D; Yuste C; Panizo N; Verde E; Muñoz MA; Luño J
    J Nephrol; 2012; 25(6):969-75. PubMed ID: 22241639
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Can Pentoxifylline be used as Adjunct Therapy to ACE Inhibitors and ARBs in Preserving Kidney Function?
    Carson C; Al-Makki A; Shepler B
    J Pharm Pharm Sci; 2016; 19(1):1-7. PubMed ID: 27096690
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of Statins on Kidney Disease Outcomes: A Systematic Review and Meta-analysis.
    Su X; Zhang L; Lv J; Wang J; Hou W; Xie X; Zhang H
    Am J Kidney Dis; 2016 Jun; 67(6):881-92. PubMed ID: 26905361
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early change in proteinuria as a surrogate end point for kidney disease progression: an individual patient meta-analysis.
    Inker LA; Levey AS; Pandya K; Stoycheff N; Okparavero A; Greene T;
    Am J Kidney Dis; 2014 Jul; 64(1):74-85. PubMed ID: 24787763
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis.
    Bose B; Badve SV; Hiremath SS; Boudville N; Brown FG; Cass A; de Zoysa JR; Fassett RG; Faull R; Harris DC; Hawley CM; Kanellis J; Palmer SC; Perkovic V; Pascoe EM; Rangan GK; Walker RJ; Walters G; Johnson DW
    Nephrol Dial Transplant; 2014 Feb; 29(2):406-13. PubMed ID: 24042021
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biotic Supplements for Renal Patients: A Systematic Review and Meta-Analysis.
    Pisano A; D'Arrigo G; Coppolino G; Bolignano D
    Nutrients; 2018 Sep; 10(9):. PubMed ID: 30181461
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the effect of pentoxifylline and captopril on proteinuria in patients with type 2 diabetes mellitus.
    Aminorroaya A; Janghorbani M; Rezvanian H; Aminian T; Gharavi M; Amini M
    Nephron Clin Pract; 2005; 99(3):c73-7. PubMed ID: 15665549
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinical state of a patient with nephrotic proteinuria successfully treated with combined therapy with angiotensin II receptor antagonists and angiotensin II converting enzyme inhibitors and pentoxifylline].
    Renke M; Rutkowski P; Tylicki L; Zietkiewicz M; Larczyński W; Rutkowski B
    Przegl Lek; 2008; 65(6):312-4. PubMed ID: 18853664
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nonalbumin proteinuria is a simple and practical predictor of the progression of early-stage type 2 diabetic nephropathy.
    Kim JH; Kim SS; Kim IJ; Lee MJ; Jeon YK; Kim BH; Song SH; Kim YK
    J Diabetes Complications; 2017 Feb; 31(2):395-399. PubMed ID: 27913013
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Will the addition of pentoxifylline reduce proteinuria in patients with diabetic glomerulosclerosis refractory to maximal doses of both an angiotensin-converting enzyme inhibitor and an angiotensin receptor blocker?
    Diskin CJ; Stokes TJ; Dansby LM; Radcliff L; Carter TB
    J Nephrol; 2007; 20(4):410-6. PubMed ID: 17879206
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dietary Salt Restriction in Chronic Kidney Disease: A Meta-Analysis of Randomized Clinical Trials.
    Garofalo C; Borrelli S; Provenzano M; De Stefano T; Vita C; Chiodini P; Minutolo R; De Nicola L; Conte G
    Nutrients; 2018 Jun; 10(6):. PubMed ID: 29882800
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Effects of statins on delaying progression of chronic kidney disease: a meta-analysis].
    Liu ZR; Zhao H; Chen YR; Tang DD; Niu HX
    Nan Fang Yi Ke Da Xue Xue Bao; 2016 Apr; 36(4):445-54. PubMed ID: 27113168
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Emerging therapies for chronic kidney disease: what is their role?
    Vilayur E; Harris DC
    Nat Rev Nephrol; 2009 Jul; 5(7):375-83. PubMed ID: 19455178
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.